Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

Abstract

These findings of synergistic glioblastoma stem cell killing by bortezomib and three different FDA-approved HDAC inhibitors confirm and expand previous observations on co-operative effects between these classes of drugs.